Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Cell-based gene therapy holds a great promise for the treatment of human malignancy. Among different cells, mesenchymal stem cells (MSCs) are emerging as valuable anti-cancer agents that have the potential to be used to treat a number of different cancer types. They have inherent migratory properties, which allow them to serve as vehicles for delivering effective therapy to isolated tumors and metastases. MSCs have been engineered to express anti-proliferative, pro-apoptotic, and anti-angiogenic agents that specifically target different cancers. Another field of interest is to modify MSCs with the cytokines that activate pro-tumorigenic immunity or to use them as carriers for the traditional chemical compounds that possess the properties of anti-cancer drugs. Although there is still controversy about the exact function of MSCs in the tumor settings, the encouraging results from the preclinical studies of MSC-based gene therapy for a large number of tumors support the initiation of clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dasari, V. R., Kaur, K., Velpula, K. K., Gujrati, M., Fassett, D., Klopfenstein, J. D., Dinh, D. H., & Rao, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010350 · Cited by 151 · cited 2×
“PTEN upregulation influenced Akt expression pattern, causing PI3K/Akt pathway disruption and leading to the inhibition of growth and migration of cancer cells [44].”
RetractedMesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992 · cited 1×
“Afterward, the term ‘‘MSCs’’ was adopted by the Caplan group to define a population of stem cells with a three-lineage differentiation potential [20].”
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., Nguyen, A. T., Malide, D., Combs, C. A., Hall, G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051921 · Cited by 747
Decoding Cell Death Signals in Inflammation and Immunity
Zitvogel, L., Kepp, O., & Kroemer, G. (2010) · Cell · doi:10.1016/j.cell.2010.02.015 · Cited by 558 · cited 1×
“Tumor-specific IFN-g -producing CD8 + T-cell immune response is important to the outcomes of cancer-bearing animals [150].”
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2
Lawler, P. R., & Lawler, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006627 · Cited by 532 · cited 1×
“Another important factor is thrombospondin-1 (TSP-1), a matricellular protein that is widely considered to be involved in the inhibition of angiogenesis and tumorigenesis [126,127].”
Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431 · cited 1×
“Concordantly, a significant inhibition of tumor growth was observed in the colon cancer and prostate cancer mice models after the CD-engineered AT-MSC administration [111,112].”
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417 · cited 2×
“have shown that human BM-MSCs transduced with the TRAIL gene caused lung, breast, squamous, and cervical cancer cell apoptosis and death in coculture experiments [140].”
Severino, V, Alessio, N., Farina, A., Sandomenico, A., Cipollaro, M., Peluso, G., Galderisi, U., & Chambery, A. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.445 · Cited by 214
Wang, Y., Zhang, Z., Chi, Y., Zhang, Q., Xu, F., Yang, Z., Meng, L., Yang, S., Yan, S., Mao, A., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.480 · Cited by 185 · cited 1×
“Issues regarding MSC transformation are very controversial, and both spontaneous and induced transformation have been reported [205,206].”
Chen, X., Lin, X., Zhao, J., Shi, W., Zhang, H., Wang, Y., Kan, B., Du, L., Wang, B., Wei, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.3 · Cited by 173
Kucerova, L., Matuskova, M., Pastorakova, A., Tyciakova, S., Jakubikova, J., Bohovic, R., Altanerova, V., & Altaner, C. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1239 · Cited by 171 · cited 1×
“Nonetheless, CD overexpressing MSCs were successfully used in glioma [103–106], glioblastoma [10], osteosarcoma [107], gastric cancer [108], medullary thyroid carcinoma [109], and melanoma experiments [110], showing the evident anti-cancer activity of the therapeutic cells with good prognosis for future clinical trial…”
Seo, S. H., Kim, K. S., Park, S. H., Suh, Y. S., Kim, S. J., Jeun, S.-S., & Sung, Y. C. (2011) · Gene Therapy · doi:10.1038/gt.2010.170 · Cited by 148 · cited 3×
“In another report, the anti-tumor effect of MSCs that produced IL-12 was also confirmed in kidney cancer, cervical cancer, and Ewing sarcoma models [135–137].”
Eiró, N., Sendon-Lago, J., Seoane, S., Bermúdez, M. A., Lamelas, M. L., Garcia-Caballero, T., Schneider, J., Perez-Fernandez, R., & Vizoso, F. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2530 · Cited by 92
Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Therapy
Eliopoulos, N., Francois, M., Boivin, M.-N., Martineau, D., & Galipeau, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0160 · Cited by 90 · cited 1×
“Similarly, murine BM-MSCs retrovirally engineered to secrete IL-12 significantly reduced breast cancer growth when delivered subcutaneously in syngeneic and allogeneic hosts [157].”
Ma, Y., Hao, X., Zhang, S., & Zhang, J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1774-x · Cited by 85 · cited 2×
“UC-MSCs exert their inhibitory effect by initiating cell cycle arrest on breast cancer cells both in vitro and in vivo [48], and BM-MSCs were proved to reduce metastasis in vivo [64].”
Duan, X., Guan, H., Cao, Y., & Kleinerman, E. S. (2009) · Cancer · doi:10.1002/cncr.24013 · Cited by 79
Bonomi, A., Sordi, V., Dugnani, E., Ceserani, V., Dossena, M., Coccè, V., Cavicchini, L., Ciusani, E., Bondiolotti, G., Piovani, G., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.09.005 · Cited by 56 · cited 1×
“GCB-loaded MSCs integrated into the tumor mass, therefore, were capable of delivering much higher amounts of the drug in situ than could be achieved by intravenous injection [204].”
IFN-γ-Secreting-Mesenchymal Stem Cells Exert an Antitumor Effect In Vivo via the TRAIL Pathway
Yang, X., Du, J., Xu, X., Xu, C., & Song, W. (2014) · Journal of Immunology Research · doi:10.1155/2014/318098 · Cited by 52
Influence of mesenchymal stem cells on metastasis development in mice in vivo
Meleshina, A. V., Cherkasova, E. I., Shirmanova, M. V., Klementieva, N. V., Kiseleva, E. V., Snopova, L. В., Prodanets, N. N., & Zagaynova, E. V. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0003-7 · Cited by 45
Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model
Pessina, A., Leonetti, C., Artuso, S., Benetti, A., Dessy, E., Pascucci, L., Passeri, D., Orlandi, A., Berenzi, A., Bonomi, A., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0200-3 · Cited by 39
Genetic Engineering of Mesenchymal Stem Cells for Regenerative Medicine
Nowakowski, A., Walczak, P., Janowski, M., & Lukomska, B. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0062 · Cited by 38 · cited 1×
“Ac-cumulating evidence indicates that MSCs transplanted in different pathological conditions are home to the sites of tissue injury and induce the recruitment of endogenous cells, tissue remodeling, and anti-inflammatory activities [1–3].”
Self-citationNguyenThai, Q., Sharma, N., Luong, D. H., Sodhi, S. S., Kim, J., Kim, N., Oh, S., & Jeong, D. K. (2015) · The Journal of Gene Medicine · doi:10.1002/jgm.2826 · Cited by 28
Cited by
Concise Review: Mesenchymal Stem Cells: From Roots to Boost
Andrzejewska, A., Lukomska, B., & Janowski, M. (2019) · Stem Cells · doi:10.1002/stem.3016 · Cited by 611
Self-citationMesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1078-8 · Cited by 122
Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
Metadata
- Authors
- Nowakowski, A., Drela, K., Rozycka, J., Janowski, M., & Lukomska, B.
- Venue
- Stem Cells and Development
- Publisher
- SAGE Publications
- Published
- 2016-10-15
- Volume
- 25
- Issue
- 20
- Pages
- 1513-1531
- ISSN
- 1525-8165 (ISSN-L)
- 1547-3287
- 1557-8534
- OpenAlex
- W2518770527
- Cited by
- 60
- References
- 23
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.